Navigation Links
URMC heart research expands to Asia with launch of new device trial
Date:8/9/2013

Cardiologists at the University of Rochester Medical Center are launching a new study in an effort to improve the treatment of a very common form of heart disease in the Asian population.

Called MADIT-Asia, the study is the first to test cardiac resynchronization therapy a device that improves the mechanical pumping action of the heart in Asian patients with non-coronary heart disease. Though the majority of heart disease in the United States is caused by cholesterol-clogged arteries that restrict blood flow from the coronary arteries to the heart, the opposite is true in Asia, where there's a much higher proportion of heart disease that's caused by virus or, in many cases, unknown factors.

"This study is important because there has been almost no research related to the treatment of non-ischemic or non-coronary heart disease in this population; most trials have taken place in the United States and Europe," noted principal investigator Arthur J. Moss, M.D., cardiology professor at the University of Rochester Medical Center and a leading expert on cardiac device therapy.

Moss says the study is also the first to test an innovative approach using two leads or wires instead of the usual three to send electrical impulses from the cardiac resynchronization therapy device to the heart to help it beat in a more balanced way. The leads, which are positioned in specific spots in the heart at the time of device implantation, can get infected, fracture, or even pierce a vein if not positioned properly by a skilled clinician.

"Preliminary evidence suggests that a two-lead system is just as effective, if not more effective, than a three-lead system," said Moss. "Fewer leads would be better and would most likely translate into fewer complications for patients."

The trial, sponsored by Boston Scientific, will enroll 180 patients from China, Hong Kong (part of China, but medically it operates differently), Japan, South Korea, Taiwan, Singapore, Thailand, Malaysia and India. Half of the patients will receive cardiac resynchronization therapy using two leads plus standard medical management and the other half will be managed medically. The team, which is ready to enroll the first patients in the trial, will use echocardiogram readings to determine improvement in heart function in each group.

This is the latest trial in the series of MADIT (Multicenter Automatic Defibrillator Implantation Trial) studies, which Moss has led since their inception in the early 1990's. His major findings include: Preventive therapy with an implantable cardioverter defibrillator or ICD significantly reduces the risk of death in heart attack survivors; cardiac resynchronization therapy plus defibrillator (CRT-D therapy) prevents the progression of heart failure in patients living with mild forms of the disease; and a simple change in the way physicians program CRT-D devices dramatically reduces inappropriate therapies potentially painful shocks delivered for rhythms that aren't life threatening and significantly increases survival in people with heart disease.

Moss holds no stock in any device company, has never been a member of any corporate speakers bureau and since December 1, 2008, has chosen not to accept honoraria from Boston Scientific for any professional activity.


'/>"/>

Contact: Emily Boynton
emily_boynton@urmc.rochester.edu
585-273-1757
University of Rochester Medical Center
Source:Eurekalert

Related medicine news :

1. Heartburn No More System Review Exposes New Efficient Heartburn Treatment
2. Study: Heart pump with behind-the-ear power connector
3. Santa Rosa Boot Camp Celebrates Successful 1,000lb Meltdown Challenge by Donating All Proceeds to the American Heart Association
4. UC Davis "Lab on a Chip" Measures Heart Disease Risk
5. MedHelp to Host Online Chat on How Cancer Treatment Can Affect Heart Health
6. AED.com Encourages Kidd Kraddick Fans to Examine Their Heart Health
7. Beaumont Health System Launches Research Trial of Bioresorbable Heart Scaffold
8. Researchers identify genetic mutation linked to congenital heart disease
9. Beaumont Health System launches research trial of bioresorbable heart scaffold
10. A Checklist for Heart Attack Prevention, from the July 2013 Harvard Men's Health Watch
11. Increased Risk of Heart Disease Associated With Long-Term Obesity Article Published by Health News Wires
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... Monica, CA (PRWEB) , ... March 28, 2017 ... ... Dr. Carson Liu of SkyLex Advanced Surgical, Inc. is thrilled to offer the ... gastric balloon procedure, and this procedure adds to SkyLex Advanced Surgical’s already ...
(Date:3/28/2017)... ... , ... With expansion and efficiency in mind, Patten Seed Company completed relocation ... plant opened in Marshallville in 2006, and a bagging and shipping facility has been ... of Patten Seed operations to the Middle Georgia location from their previous home in ...
(Date:3/28/2017)... ... ... Thank you to all who attended Capio Partners Winter 2017 Healthcare Leadership ... to providers and offered an opportunity to collaborate and network with healthcare colleagues across ... where attendees gathered for a lively discussion on trends and issues that healthcare leaders ...
(Date:3/28/2017)... ... ... Bacteria and fungi are probably not the first ingredients that come to mind when thinking ... in your diet can actually improve health outcomes. And the good news is they may ... a new peer-reviewed paper led by Maria Marco, Ph.D. , University of ...
(Date:3/27/2017)... ... March 27, 2017 , ... Drs. Bruce Trimble ... without requiring a referral. Trimble Dental offers a variety of services to ... dental implants. Whether patients have discolored, crooked or missing teeth in Eau Claire, ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017 ... expected to reach a value of USD 4.5 billion ... View Research, Inc. Proper closure of injured tissues post ... and function. Postoperative leakages occur in 3% to 15% ... They are responsible for one third of postoperative deaths ...
(Date:3/27/2017)... , March 27, 2017 ... to better understand Bayer and its partnering interests and activities ... 2010 report provides an in-depth insight into the partnering activity ... On demand company reports are prepared upon purchase to ... company data. The report will be delivered in ...
(Date:3/27/2017)... 2017  Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or ... shares of common stock in an underwritten public offering ... the Securities and Exchange Commission (the "SEC"). The offering ... can be no assurance as to whether or when ... actual size or terms of the offering. Cryoport also ...
Breaking Medicine Technology: